Immune checkpoint inhibitor (ICI) therapy has greatly improved treatment of various
advanced cancers but increasing use of ICI therapy has exposed the risk of ICI-related …

Harnessing the power of the immune system to target cancer cells has been the subject of
research for more than a decade. In 1891, Dr William Coley injected beta-hemolytic …

Objective To estimate the incidence of immune checkpoint inhibitor–related myositis (ICI‐
myositis) in cancer patients receiving ICIs, and to report associated clinical manifestations …

Cardiotoxicity is a well-recognised side effect of cancer-related therapies with a great impact
on outcomes and quality of life in the cancer survivor population. The pathogenesis of …

Within the past decade, immune-checkpoint inhibitors (ICPIs), including anti-programmed
cell death 1 (PD-1), anti-programmed cell death 1 ligand 1 (PD-L1), and anti-cytotoxic T …

This article discusses the current clinical and research landscape with respect to
cardiovascular magnetic resonance (CMR) imaging in several types of cardiotoxicity related …

Background Immune checkpoint inhibitors (ICI) have revolutionized the management of
many cancer types by drastically improving the median survival rate of patients. However …

Abstract Purpose of Review Cancer treatment–related cardiotoxicity (CTRC) represents a
significant cause of morbidity and mortality worldwide. The purpose of our review is to …

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) are a new class of anticancer
drugs that enhance the immune system function and activate T cells against cancerous cells …

Abstract Importance: Immune checkpoint inhibitors (ICIs) are a class of immunotherapies
that have significant clinical efficacy in treating many cancer types, but they are also …